Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian Cancer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St dips after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| (NASDAQ: PPCB) | Delayed: 0.27 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.27 | 52 Week High | $ | |||
| Open | $0.28 | 52 Week Low | $ | |||
| Day High | $0.28 | P/E | N/A | |||
| Day Low | $0.25 | EPS | $ | |||
| Volume | 66,929 | |||||
